(Reuters) – Novavax Inc said on Monday its combined flu and COVID-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study.
The company said the NanoFlu/NVX-CoV2373 vaccine elicited robust responses to both influenza A and B and protected against the SARS-CoV-2 virus.
“Seasonal influenza and COVID-19 combination vaccines will likely be critical to combating emerging COVID-19 variants,” said Russell Wilson, the executive vice president and NanoFlu general manager of Novavax.
Hamsters that received the combined vaccine had heightened levels of COVID-19 antibodies two weeks after the first immunization, which increased significantly after a second dose, compared to animals that received the COVID-19 vaccine, NVX-CoV2373, alone, the company said.
Results from the animal tests were published as a preprint on the bioRxiv server last week (https://bit.ly/3o1HCaL).
Novavax said it expects to start clinical studies of the combined vaccine by the end of 2021.
Source: Read Full Article